Structure substrate binding

Bjelic S, J Aqvist (2004) Computational prediction of structure, substrate binding mode, mechanism, and rate for a malaria protease with a novel type of active site. Biochemistry 43 (46) 14521-14528... 

As shown in this chapter, theoretical treatments of P450 problems have come of age, and they enable the study of many features related to the three-dimensional structures, the electronic structures, substrate binding, reactivity, and dynamics of the various physical processes in the cycle. This ability will only increase with time, as the various techniques will be brought to bear simultaneously on a given problem. Techniques similar to combinatorial sjmthesis will have to be adopted in order to screen fast many alternative possibilities. 

P450epoK presents a different picture. Here the substrate-free and -bound structures were separately crystallized, yet there is very little difference in structure. Substrate binding causes a... 

Key words ADP/ATP carrier - loop structure - substrate binding site -SH-reagent - mitochondria... 

Left side of Fig. 4 shows a ribbon model of the catalytic (C-) subunit of the mammalian cAMP-dependent protein kinase. This was the first protein kinase whose structure was determined [35]. Figure 4 includes also a ribbon model of the peptide substrate, and ATP (stick representation) with two manganese ions (CPK representation). All kinetic evidence is consistent with a preferred ordered mechanism of catalysis with ATP binding proceeding substrate binding. 

Figure 4.8 The active site in all a/p barrels is in a pocket formed by the loop regions that connect the carboxy ends of the p strands with the adjacent a helices, as shown schematically in (a), where only two such loops are shown, (b) A view from the top of the barrel of the active site of the enzyme RuBisCo (ribulose bisphosphate carboxylase), which is involved in CO2 fixation in plants. A substrate analog (red) binds across the barrel with the two phosphate groups, PI and P2, on opposite sides of the pocket. A number of charged side chains (blue) from different loops as welt as a Mg ion (yellow) form the substrate-binding site and provide catalytic groups. The structure of this 500 kD enzyme was determined to 2.4 A resolution in the laboratory of Carl Branden, in Uppsala, Sweden. (Adapted from an original drawing provided by Bo Furugren.)...

The theory predicts that such proteins are built up of several subunits which are symmetrically arranged and that the two states differ by the arrangements of the subunits and the number of bonds between them. In one state the subunits are constrained by strong bonds that would resist the structural changes needed for substrate binding, and this state would consequently bind substrates weakly they called it the tense or T state. In the other state, called the R state, these constraints are relaxed. 

This concerted model assumes furthermore that the symmetry of the molecule is conserved so that the activity of all its subunits is either equally low or equally high, that is, all structural changes are concerted. Subsequently Daniel Koshland, University of California, Berkeley, postulated a sequential model in which each subunit is allowed independently to change its tertiary structure on substrate binding. In this model tertiary structural changes in the subunit with bound ligand alter the interactions of this... 

Zhu, X., et al. Structural analysis of substrate binding by the molecular chaperone DnaK. Science 272 1606-1614, 1996. 

Krieger, M., Kay, L.M., Stroud, R.M. Structure and specific binding of trypsin comparison of inhibited derivatives and a model for substrate binding. /. Mol. Biol. 83 209-230, 1974. 

Inhibition of a regulatory enzyme by a feedback inhibitor does not conform to any normal inhibition pattern, and the feedback inhibitor F bears little structural similarity to A, the substrate for the regulatory enzyme. F apparently acts at a binding site distinct from the substrate-binding site. The term allosteric is apt, because F is sterically dissimilar and, moreover, acts at a site other than the site for S. Its effect is called allosteric Inhibition. 

Destabilization of the ES complex can involve structural strain, desolvation, or electrostatic effects. Destabilization by strain or distortion is usually just a consequence of the fact (noted previously) that the enzyme is designed to bind the transition state more strongly than the substrate. When the substrate binds, the imperfect nature of the fit results in distortion or strain in the substrate, the enzyme, or both. This means that the amino acid residues that make up the active site are oriented to coordinate the transition-state structure precisely, but will interact with the substrate or product less effectively. 

Figure 5.9 Models of hexo-kinase in space-filling and wireframe formats, showing the cleft that contains the active site where substrate binding and reaction catalysis occur. At the bottom is an X-ray crystal structure of the enzyme active site, showing the positions of both glucose and ADP as well as a lysine amino acid that acts as a base to deprotonate glucose.

Molecular characteristics of luciferase. A molecule of the luciferase of G. polyedra comprises three homologous domains (Li et al., 1997 Li and Hastings, 1998). The full-length luciferase (135 kDa) and each of the individual domains are most active at pH 6.3, and they show very little activity at pH 8.0. Morishita et al. (2002) prepared a recombinant Pyrocystis lunula luciferase consisting of mainly the third domain. This recombinant enzyme catalyzed the light emission of luciferin (luminescence A.max 474 nm) and the enzyme was active at pH 8.0. The recombinant enzyme of the third domain of G. polyedra luciferase was crystallized and its X-ray structure was determined (Schultz et al., 2005). A -barrel pocket putatively for substrate binding and catalysis was identified in the structure, and... 

Bednarczyk D, Ekins S, Wikel JH and Wright SH. Influence of molecular structure on substrate binding to the human organic cation transporter, hOCTl. Mol Pharmacol 2003 63 489-98. 

---